Immunotherapeutic Innovations in Clear Cell Renal Cell Carcinoma: Current Strategies and Future Directions

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Clear cell kidney cancer (ccRCC) accounts for approximately 80% of kidney cancers globally.
• A significant majority of ccRCC cases involve inactivating mutations in the Von Hippel-Lindau (VHL) gene.
• VHL gene mutations lead to the stabilization of hypoxia-inducible factors (HIFs), promoting angiogenesis through vascular endothelial growth factor (VEGF) over-expression.

Purpose of the Study:

• To review the current understanding of ccRCC biology, focusing on the role of VHL gene mutations and VEGF.
• To discuss existing anti-angiogenic treatments (AAT) and immune checkpoint inhibitors (ICIs) used for ccRCC.
• To highlight the need for further research into ccRCC pathophysiology and resistance mechanisms for novel therapy development.

Main Methods:

• Literature review of studies on ccRCC genetics, angiogenesis, and treatment modalities.
• Analysis of the molecular pathways involved in ccRCC development, including VHL-HIF-VEGF axis.
• Examination of current therapeutic strategies, such as anti-VEGF therapies, tyrosine kinase inhibitors, and immune checkpoint inhibitors.

Main Results:

• VHL gene inactivation is a key driver in ccRCC, leading to increased VEGF and promoting tumor vascularization.
• Current treatments include anti-angiogenic agents (e.g., VEGF inhibitors, TKIs) and immune checkpoint inhibitors (anti-PD-1, anti-PD-L1, anti-CTLA-4).
• VEGF and VEGFC play roles in angiogenesis, lymph-angiogenesis, and immune evasion in the tumor microenvironment.

Conclusions:

• Despite advances in anti-angiogenic and immunotherapies, ccRCC remains a challenging malignancy to treat effectively.
• Understanding the tumor microenvironment and resistance mechanisms is crucial for developing improved ccRCC therapies.
• Further research is essential to uncover new therapeutic targets and strategies for kidney cancer treatment.